Effect of Rosiglitazone Versus Placebo on Cardiovascular Performance and Myocardial Triglyceride
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if rosiglitazone treatment improves integrated
cardiovascular performance in patients at risk for congestive heart failure. A second aim of
this study is to determine if treatment with rosiglitazone decreases intracellular (ectopic)
triglyceride (TG) deposition in cardiomyocytes using nuclear magnetic resonance (NMR)
techniques, and how changes in intra-myocardial lipid content relate to changes in cardiac
structure and function.